Abstract:Abstract BACKGROUND Glioblastoma (GBM), a WHO Grade IV glioma, is one of the most lethal brain tumors. In spite of the standard of care and currently developed advanced treatment, the prognosis of GBM patients is still poor. In addition to the understanding of GBM cells, the microenvironment plays a critical role in regulating GBM progression. Also, more and more information indicates the interaction of GBM-associated macrophages (GAMs) and GBM cells facilitates GBM progression via sculpturing immunosurveillance, cancer stemness, and cancer resistance. And thus, we hypothesized that GBM cells sculptured the microenvironment via macrophage alternation of which interventions may potentialize immune checkpoint blockade therapy. MATERIAL AND METHODS The bulk RNA sequencing (seq.) of the paired primary-recurrent GBM specimens, single-cell RNA seq., in vitro (including mRNA, protein, and cell behavior tests), and in vivo validation, were integrated to explore our hypothesis. RESULTS The bulk RNA seq. of the paired primary-recurrent GBM specimens showed recurrent GBM enhanced the neuroinflammation pathway. Among the secretory components, CXCL12, also known as stromal cell-derived factor 1 was accumulated during GBM progression and upregulated in temozolomide (TMZ)-resistant GBM cells compared with parental GBM cell lines. In addition, the newly CXCL12 receptor CXCR7 may act as a scavenger to breakdown CXCL12-CXCR4 positive feedback in GBM resistance. Moreover, the bulk RNA sequencing seq. showed that recurrent GBM reduced CXCR7 expression. Single-cell RNA seq. of GBM patients’ specimens suggested that CXCR7 was majorly expressed in GBM cells than in normal neural and immune cells. Developing TMZ resistance in GBM cell lines also down-regulated CXCR7 expression. Furthermore, silencing CXCR7 attenuated TMZ cytotoxicity while silencing CXCR7 and CXCL12 simultaneously reversed the effects. In contrast, combining CXCR7 agonists and TMZ enhanced TMZ cytotoxicity Otherwise, the GBM-associated CXCL12 activated M0 macrophages into GAMs by facilitating macrophage proliferation and inducing pro-tumor factors, including IL-1β and its receptors, IL-6, MMP9, and immune checkpoint PD-L1. Mechanistically, GBM-associated CXCL12 upregulated PD-L1 in GAMs via NF-κB. Also, in the orthotopic GBM mouse model, CXCR7 knockdown in GBM cells led to poor survival and increased PD-L1 expression in GAMs. Finally, we combined CXCR7 agonist and anti-PD-L1 to show prolonged survival, in contrast, anti-PD-L1 did not show this effect. CONCLUSION In accordance with the multimodal analysis, GBM regulated the accumulation of CXCL12 via silencing CXCR7 in GBM cells. The CXCR7-CXCL12 axis confers the immunosuppression by up-regulating PD-L1 in GAMs. Our study suggested that CXCR7 activation treatment alone or combined with an immune checkpoint inhibitor may be a potential strategy for the treatment of GBM.

Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages

HDAC7 Drives Glioblastoma to a Mesenchymal-Like State Via LGALS3-mediated Crosstalk Between Cancer Cells and Macrophages

β2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages

The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity in a spatiotemporal context

Supplementary Data 1 from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages

2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages

IMMU-07. THE CXCL16/CXCR6 AXIS REGULATES CD8+ T-CELL RECRUITMENT AND FUNCTION IN GLIOBLASTOMA

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage

P12.03.A MULTIMODAL ANALYSIS OF GLIOBLASTOMA REVEALS THE POTENTIAL OF CXCR7-CXCL12 IN GBM CELLS SENSITIZES GBM TO IMMUNE CHECKPOINT BLOCKADE THERAPY

Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM

Exosomal miR-6733-5p mediates cross-talk between glioblastoma stem cells and macrophages and promotes glioblastoma multiform progression synergistically

Hypoxia-induced TREM1 Promotes Mesenchymal-Like States of Glioma Stem Cells Via Alternatively Activating Tumor-Associated Macrophages

The CEBPB+ glioblastoma subcluster specifically drives the formation of M2 tumor-associated macrophages to promote malignancy growth

Abstract LT05: METTL8-MEDIATED EPITRANSCRIPTOMIC REGULATION OF GBM CYCLING STATE IS DEPENDENT ON RTK/PI3K/AKT SIGNALING

Single-cell transcriptomics reveals immunosuppressive microenvironment and highlights stumor-promoting macrophage cells in Glioblastoma

FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells

The GBM Tumor Microenvironment as a Modulator of Therapy Response: ADAM8 Causes Tumor Infiltration of Tams through HB-EGF/EGFR-Mediated CCL2 Expression and Overcomes TMZ Chemosensitization in Glioblastoma

ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages

The PTPRZ1-MET/STAT3/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization

Dual Role of WISP1 in Maintaining Glioma Stem Cells and Tumor-Supportive Macrophages in Glioblastoma

The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential